Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

Driven by new product successes and strategic investments, Eli Lilly and Co (LLY) reports a 42% revenue increase, setting a ...

They used propensity matching to compare 1,925 adolescents who took semaglutide (Wegovy), liraglutide (Saxenda), dulaglutide ...

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

However, Eli Lilly continued to develop GLP-1 drugs, getting Trulicity, which is used to treat type 2 diabetes, approved in 2014. By 2018, Trulicity would become Eli Lilly's top-selling drug ...